MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Status:
Active, not recruiting
Trial end date:
2023-05-15
Target enrollment:
Participant gender:
Summary
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who
have been hospitalized with the infection. Participants in the study will be treated with
either MP0420 plus current standard of care (SOC), or with placebo plus current SOC. This is
ACTIV-3/TICO Treatment Trial H5.
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota
Collaborators:
AIDS Clinical Trials Group Cardiothoracic Surgical Trials Network (CTSN) International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Kirby Institute Medical Research Council Molecular Partners AG National Heart, Lung, and Blood Institute (NHLBI) Prevention and Early Treatment of Acute Lung Injury (PETAL) University of Copenhagen US Department of Veterans Affairs Washington D.C. Veterans Affairs Medical Center